Cargando…
Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation
Efficient osteogenic differentiation of mesenchymal stem cells (MSCs) is a critical step in the treatment of bone defects and skeletal disorders, which present challenges for cell-based therapy and regenerative medicine. Thus, it is necessary to understand the regulatory agents involved in osteogene...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594482/ https://www.ncbi.nlm.nih.gov/pubmed/33115508 http://dx.doi.org/10.1186/s13287-020-01966-3 |
_version_ | 1783601649158193152 |
---|---|
author | Ghorbaninejad, Mahsa Khademi-Shirvan, Maliheh Hosseini, Samaneh Baghaban Eslaminejad, Mohamadreza |
author_facet | Ghorbaninejad, Mahsa Khademi-Shirvan, Maliheh Hosseini, Samaneh Baghaban Eslaminejad, Mohamadreza |
author_sort | Ghorbaninejad, Mahsa |
collection | PubMed |
description | Efficient osteogenic differentiation of mesenchymal stem cells (MSCs) is a critical step in the treatment of bone defects and skeletal disorders, which present challenges for cell-based therapy and regenerative medicine. Thus, it is necessary to understand the regulatory agents involved in osteogenesis. Epigenetic mechanisms are considered to be the primary mediators that regulate gene expression during MSC differentiation. In recent years, epigenetic enzyme inhibitors have been used as epidrugs in cancer therapy. A number of studies mentioned the role of epigenetic inhibitors in the regulation of gene expression patterns related to osteogenic differentiation. This review attempts to provide an overview of the key regulatory agents of osteogenesis: transcription factors, signaling pathways, and, especially, epigenetic mechanisms. In addition, we propose to introduce epigenetic enzyme inhibitors (epidrugs) and their applications as future therapeutic approaches for bone defect regeneration. |
format | Online Article Text |
id | pubmed-7594482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75944822020-10-30 Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation Ghorbaninejad, Mahsa Khademi-Shirvan, Maliheh Hosseini, Samaneh Baghaban Eslaminejad, Mohamadreza Stem Cell Res Ther Review Efficient osteogenic differentiation of mesenchymal stem cells (MSCs) is a critical step in the treatment of bone defects and skeletal disorders, which present challenges for cell-based therapy and regenerative medicine. Thus, it is necessary to understand the regulatory agents involved in osteogenesis. Epigenetic mechanisms are considered to be the primary mediators that regulate gene expression during MSC differentiation. In recent years, epigenetic enzyme inhibitors have been used as epidrugs in cancer therapy. A number of studies mentioned the role of epigenetic inhibitors in the regulation of gene expression patterns related to osteogenic differentiation. This review attempts to provide an overview of the key regulatory agents of osteogenesis: transcription factors, signaling pathways, and, especially, epigenetic mechanisms. In addition, we propose to introduce epigenetic enzyme inhibitors (epidrugs) and their applications as future therapeutic approaches for bone defect regeneration. BioMed Central 2020-10-28 /pmc/articles/PMC7594482/ /pubmed/33115508 http://dx.doi.org/10.1186/s13287-020-01966-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Ghorbaninejad, Mahsa Khademi-Shirvan, Maliheh Hosseini, Samaneh Baghaban Eslaminejad, Mohamadreza Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
title | Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
title_full | Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
title_fullStr | Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
title_full_unstemmed | Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
title_short | Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
title_sort | epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594482/ https://www.ncbi.nlm.nih.gov/pubmed/33115508 http://dx.doi.org/10.1186/s13287-020-01966-3 |
work_keys_str_mv | AT ghorbaninejadmahsa epidrugsnovelepigeneticregulatorsthatopenanewwindowfortargetingosteoblastdifferentiation AT khademishirvanmaliheh epidrugsnovelepigeneticregulatorsthatopenanewwindowfortargetingosteoblastdifferentiation AT hosseinisamaneh epidrugsnovelepigeneticregulatorsthatopenanewwindowfortargetingosteoblastdifferentiation AT baghabaneslaminejadmohamadreza epidrugsnovelepigeneticregulatorsthatopenanewwindowfortargetingosteoblastdifferentiation |